Benvenue Medical is exhibiting the Luna 3D Multi-Expandable Interbody Fusion System and Kiva VCF Treatment System at the North American Spine Society (NASS) 31st Annual Meeting taking place Oct. 26-29 in Boston.
Benvenue is one of eight companies selected to present in the Innovative Technology Presentations Session.
Dr. Jeffrey Coe of the Silicon Valley Spine Institute (Campbell, California) will provide an overview of the Luna 3D system and discuss early clinical results in the presentation, “Multiexpandable Cage for Minimally Invasive Posterior Lumbar Interbody Fusion,” on Oct. 26.
“The Luna 3D System further advances minimally invasive lumbar fusion surgical techniques,” said Dr. Coe.
“An important advantage of Luna’s multi-expandable cage for fusion is that it allows us to restore disc height using a well-established posterior surgical approach while providing stable fixation via a larger construct that is more often achieved using an anterior approach.”
The Luna 3D Interbody Fusion System is designed to provide one of the largest yet least invasive devices for posterior lumbar interbody spinal fusion.
Cleared by the U.S. Food and Drug Administration in November 2014, the Luna 3D System is comprised of a PEEK implant designed to expand in multiple dimensions within the disc space, first in footprint and secondarily in height, allowing surgeons to effectively restore height via a posterior approach while providing the stability of a larger construct more often associated with an anterior approach.
After a discectomy is performed, the Luna 3D Implant is delivered through a small diameter cannula into the disc space. After expanding its footprint, it is then expanded in height with the insertion of a middle section. When the cannula is removed, bone graft is placed in the middle of the implant and the implant is locked in place with a locking wire.
The Kiva VCF Treatment System provides a new implant-based approach to vertebral augmentation in the treatment of painful VCFs. Kiva was recently launched in the U.S. and it is commercially available in Europe.
Kiva has been shown, in at least three comparative studies with a total of more than 500 patients, to meet or exceed the performance of balloon kyphoplasty, the standard of care. Kiva is indicated for the reduction and treatment of spine fractures in the thoracic and/or lumbar spine from T6-L5. It is intended to be used in combination with the Benvenue Vertebral Augmentation Cement Kit.